The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Invitrocue (IVQ) has completed CE Mark registration for its Onco-PDO cancer test, enabling the sale of the product in the European Economic Region
  • The CE Mark requires a declaration that the product meets EU standards for health, safety and environmental protection
  • Onco-PDO will soon be commercially available to oncologists and patients across Europe, starting with Germany and Spain
  • Despite the good news, company shares are still locked up
  • Invitrocue stock has been suspended since August 2019, last trading for six cents each

Invitrocue (IVQ) has completed CE Mark registration for its Onco-PDO cancer test, enabling the sale of the product in the European Economic Region.

Headquartered in Singapore, with operations in Australia, China, Hong Kong and Germany, the company specialises in developing cell-based testing methods to provide key insights into liver toxicology, infectious diseases and oncology. 

Invitrocue’s Onco-PDO product offers an alternative to the “one-size-fits-all” approach that is common in treatments for cancer patients. 

The company’s proprietary test takes a more personalised approach, enabling medical professionals to prescribe the most appropriate treatment program based on cancer cell phenotypic resistance or the patient’s response to specific chemotherapeutic drugs.

Registration for the CE Mark requires a declaration from the company that the product meets all EU standards for health, safety and environmental protection. 

Dr. Andreas Lindner, CEO of Invitrocue Germany, commented on the milestone achievement.

“We are very pleased that Onco-PDO has successfully registered for the CE Mark, as Europe is a big market where we can offer our test,” Andreas explained.

“We are looking forward to helping doctors in the region make more informed decisions about the best treatment path for cancer patients,” he said.

Onco-PDO will soon be commercially available to oncologists and patients across Europe, starting in Germany and then Spain. Invitrocue also has plans to enter other markets, including Brazil.

The company will also be seeking to list the Onco-PDO test under the German Healthcare reimbursement system, although this is likely to occur later this year.

Despite the good news, company shares are still locked up.

Invitrocue stock has been suspended since August 2019, last trading for six cents each

IVQ by the numbers
More From The Market Online
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
The Market Online Video

Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts.
Illustration representing big data technology.

Opyl forms JV with UK and US consortium to bring products to the world

Medical technology and AI company Opyl Ltd is set to form a joint venture with UK…
Ai gen brain scan

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

EMVision Medical Devices (ASX:EMV) has announced its successful fabrication of a portable on-the-spot brain scanning device.